Biotech Stocks At 52-Week Highs - COAG, ALMR, PGNY, TXG, VMD
Biotech stocks hit 52-week highs on July 14, 2026. Hemab Therapeutics (COAG) reached $42.03 after positive Phase 2 results for HMB-002 and launched HMB-003. Alamar Biosciences (ALMR) hit $29.43 on a U.S. university proteomics partnership. Progyny (PGNY) rose 4% to $32; 2026 revenue guidance $1.365B-$1.405B. 10x Genomics (TXG) closed $43.98; 2026 revenue $600M-$625M. Viemed (VMD) peaked $12.61; 2026 net revenue $312M-$320M.
How this was made
The 30-second read
Why it matters
Each named company is linked to a same-day catalyst: COAG clinical results and a new candidate launch; ALMR a proteomics partnership; PGNY a 2026 revenue range; TXG a 2026 revenue range plus collaborations; VMD a 2026 net revenue range.
Market read
Traders can use the disclosed same-day catalysts to frame momentum and near-term expectation risk for each stock, especially where forward revenue ranges are provided.
What to watch
For COAG and ALMR, the article does not provide milestone timing, funding amounts, or endpoint details. For TXG, the guidance implies near-flat growth, which could cap upside if expectations were higher. For VMD, revenue range without margin or contract specifics may limit re-rating.
Background
The article is a multi-name watchlist-style roundup noting 52-week highs across several biotech and healthcare-related stocks, attributing moves to clinical updates, partnerships, and revenue estimates.
Ticker impact
Hemab Therapeutics hit a 52-week high after reporting positive Phase 2 results for HMB-002 in Von Willebrand’s disease and launching HMB-003.
Bullish bias near-term, with volatility around subsequent trial milestones.
The article cites positive clinical results plus a new candidate launch, both of which can re-rate a clinical-stage biotech, but it does not provide trial size, endpoints, or guidance for future timelines.
Alamar Biosciences reached a 52-week high on a new partnership to launch a national proteomics initiative using its NULISAseq Neuro 220 panel for Alzheimer’s.
Moderately bullish, likely more sentiment-driven until biomarker validation outcomes are disclosed.
The catalyst is a partnership and panel usage, but the article does not quantify funding, milestones, or expected commercial timelines.
Progyny shares rose over 4% to a 52-week high after the company estimated 2026 revenue of $1.365B to $1.405B.
Supportive for the stock over coming quarters, with upside/downside tied to how the range compares to consensus.
The article provides a specific 2026 revenue range and growth rate, but lacks consensus comparison and does not mention margin or earnings guidance.
10x Genomics hit a 52-week high after reporting a 2026 revenue estimate of $600M to $625M and referencing recent collaborations.
Likely range-bound to mildly bullish unless investors interpret collaborations as leading to faster monetization.
The article includes a revenue estimate and collaboration context, but the growth is described as 0% to 4% and no incremental financial impact is quantified.
Viemed Healthcare reached a 52-week high as it reiterated 2026 net revenue expectations of $312M to $320M.
Mildly supportive near-term, with follow-through dependent on subsequent profitability and demand signals.
The article provides a revenue range but no new operational metrics, contract wins, or margin outlook to confirm stronger fundamentals.
Market effects
Broad biotech and healthcare tape strength, with investors rewarding clinical-stage catalysts and forward revenue visibility.
Primarily US-listed small-to-mid biotech and healthcare sentiment; limited cross-region implications from the article alone.
Low global macro linkage; effects are mostly company-specific within US healthcare/biotech.
Counterpoint
52-week-high prints may reflect positioning and momentum rather than durable fundamentals, especially where the article lacks trial size, endpoints, or consensus comparisons.
Key entities
- companyHemab Therapeutics Holdings Inc.
Clinical-stage biotech; positive HMB-002 Phase 2 results and launch of HMB-003 cited as catalysts.
- companyAlamar Biosciences Inc.
Proteomics company; partnership to launch a national proteomics initiative using NULISAseq Neuro 220 panel.
- companyProgyny Inc.
Benefits management firm; 2026 revenue estimate of $1.365B to $1.405B cited.
- company10x Genomics Inc.
Life science tools/software; 2026 revenue estimate of $600M to $625M cited.
- companyViemed Healthcare Inc.
Home medical equipment provider; 2026 net revenue range of $312M to $320M cited.
